Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I trial of the farnesyl protein transferase (FPTASE) inhibitor L-778123 on a 14 or 28-day dosing schedule

Phase I trial of the farnesyl protein transferase (FPTASE) inhibitor L-778123 on a 14 or 28-day dosing schedule. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. 2000.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.